Lonza Group AG Lonza Group AG

Lonza Group AG

LONN

Rang in Aktien #447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aktienkurs
$766.95
Marktkapitalisierung
$53.57B
Veränderung (1 Tag)
1.35%
Veränderung (1 Jahr)
9.01%
Land
CH
Handel Lonza Group AG (LONN)

Kategorie

Healthcare
Aktien-Split-Historie für Lonza Group AG (LONN)
Die Aktie Lonza Group AG (Symbol: LONN) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 22, 2026 statt.
Eine LONN-Aktie, die vor dem Oct 22, 2026 gekauft wurde, entspricht heute 0 LONN-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
NL
1 x100
BE